Tegatrabetan (BC-2059)

Catalog No.S0733 Batch:S073302

Print

Technical Data

Formula

C28H36N4O6S2
Molecular Weight 588.74 CAS No. 1227637-23-1
Solubility (25°C)* In vitro DMSO 100 mg/mL (169.85 mM)
Water Insoluble
Ethanol Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O
2.5mg/ml Taking the 1 mL working solution as an example, add 50 μL of 50 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
Clear solution
5% DMSO 95% Corn oil
0.8mg/ml Taking the 1 mL working solution as an example, add 50 μL of 16 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Tegatrabetan (BC2059,Tegavivint) is an antagonist of β-Catenin. Tegatrabetan (BC2059) treatment disrupts the binding of β-catenin with the scaffold protein transducin β-like 1 (TBL1) and proteasomal degradation and declines in the nuclear levels of β-catenin.
Targets
β-catenin [1]
In vitro

Tegatrabetan (BC2059,Tegavivint) is an antagonist of β-Catenin. Tegatrabetan (BC2059) treatment disrupts the binding of β-catenin with the scaffold protein transducin β-like 1 (TBL1) and proteasomal degradation and declines in the nuclear levels of β-catenin.

Protocol (from reference)

Cell Assay:

[1]
  • Cell lines

    HL-60, OCI-AML3 and MV4-11 cells

  • Concentrations

    20–100 nM

  • Incubation Time

    120 h

  • Method

    Cells were treated with various concentrations of drug for 120 h.
Animal Study:

[1]
  • Animal Models

    NOD/SCID mice

  • Dosages

    5 or 10 mg/kg

  • Administration

    i.v.

Selleck's Tegatrabetan (BC-2059) has been cited by 4 publications

ATRX guards against aberrant differentiation in mesenchymal progenitor cells [ Nucleic Acids Res, 2024, 52(9):4950-4968] PubMed: 38477352
Alterations of ceramide synthesis induce PD-L1 internalization and signaling to regulate tumor metastasis and immunotherapy response [ Cell Rep, 2024, 43(8):114532] PubMed: 39046874
Cytosolic Cadherin 4 promotes angiogenesis and metastasis in papillary thyroid cancer by suppressing the ubiquitination/degradation of β-catenin [ J Transl Med, 2024, 22(1):201] PubMed: 38402159
KMT2A maintains stemness of gastric cancer cells through regulating Wnt/β-catenin signaling-activated transcriptional factor KLF11 [ Open Med (Wars), 2023, 18(1):20230764] PubMed: 38025523

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.